Tim Wollaeger

Chief Executive Officer at Harkness Pharmaceuticals, Inc.

Tim Wollaeger

Tim Wollaeger

Chief Executive Officer at Harkness Pharmaceuticals, Inc.

Overview
Career Highlights

Hybritech Incorporated
Harkness Pharmaceuticals, Inc.
Trinity Industries, Inc.

RelSci Relationships

2784

Number of Boards

15

Birthday

1944

Age

75

Contact Data
Trying to get in touch with Tim Wollaeger? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Tim Wollaeger likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman & Chief Executive Officer at Axikin Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Harkness Pharmaceuticals, Inc.

Relationship likelihood: Strong

Partner at Versant Venture Management LLC

Relationship likelihood: Strong

Chairman at Satiogen Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at Sanderling Ventures

Relationship likelihood: Strong

Founder at Asteres, Inc.

Relationship likelihood: Strong

Managing Member at Mesa Verde Ventures II LLC

Relationship likelihood: Strong

Managing Director at Sanderling Management Co. LLC

Relationship likelihood: Strong

Co-Founder at New Leaf Venture Partners LLC

Relationship likelihood: Strong

Professional at Chimerix, Inc.

Relationship likelihood: Strong

Paths to Tim Wollaeger
Potential Connections via
Relationship Science
You
Tim Wollaeger
Chief Executive Officer at Harkness Pharmaceuticals, Inc.
Education
MBA
Class of 1971

The Stanford Graduate School of Business has built an international reputation based on its innovative programs, which include: Two-year MBA Program, designed to educate business leaders One-year Stanford Sloan Master’s Program for mid-career executives PhD Program for future academics Executive Education programs for experienced managers Faculty research program Academic programs, including the two-year MBA, the 12-month Sloan Master's Program, and the PhD program, create a transformational student experience that reflects the tagline: Change lives. Change organizations. Change the world. Today the state-of-the-art Knight Management Center complex enables Stanford's innovative, globalized MBA curriculum, offering flexible classroom spaces for hands-on experiential learning small-group leadership labs, and team-based learning. It engages faculty and students across Stanford University, as well as alumni, global executives, and the broader world community.

BA Economics
Class of 1966

Yale University is an American private Ivy League research university located in New Haven, Connecticut. Founded in 1701 in the Colony of Connecticut, the university is the third-oldest institution of higher education in the United States.

Career History
Managing Director Emeritus
2002 - Current

Sanderling Ventures is an active manager which provides financing for seed and early-stage capital requirements, as well as providing management support. The firm also engages in syndicate investments for further rounds of financing. Sanderling Ventures invests in young companies operating in the health technology sector, as well as in biotechnology and pharmaceutical industries located in the US. The firm looks to take minority stake positions in its investments and as a seat on the board.

Chief Executive Officer
Current

Harkness Pharmaceuticals, Inc. develops novel therapies for obesity. The firm offers human clinical trials for its first product, an oral formulation of the peptide enterostatin for the treatment of obesity. The company was founded by Edward Dennis and Byron Rubin in 2003 and is headquartered in San Diego, CA.

Fund Advisor
Current

Sanderling Management Co. LLC, a subsidiary of Sanderling Ventures, is an American company focused on management consulting services.

Boards & Committees
Director
Current

Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company.Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California.

Director
1994 - 2008

Digirad Corp. engages in the provision of mobile healthcare solutions. It operates through the following segments: Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging. The Diagnostic Services segment offers imaging and monitoring services program as an alternative to purchasing equipment or outsourcing the procedures to another physician or imaging center. The Mobile Healthcare segment provides contract diagnostic imaging, including computerized tomography, magnetic resonance imaging, positron emission tomography, and healthcare expertise to hospitals. The Diagnostic Imaging segment develops solid-state gamma cameras, imaging systems and camera maintenance contracts integrated delivery networks, and federal institutions on a long-term contract basis. The company founded in 1997 and is headquartered in Suwanee, GA.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$10K - $50K
2006

THE MISSION OF THE SAN MATEO PUBLIC LIBRARY FOUNDATION IS TO SEEK PRIVATE FINANCIAL SUPPORT FROM THE COMMUNITY TO ENSURE HIGH QUALITY LIBRARY SERVICES WILL ALWAYS BE AVAILABLE NOW AND FOR FUTURE GENERATIONS

$1,000 - $4,999
2005

Teach For America (TFA) is a nonprofit organization whose stated mission is to "enlist, develop, and mobilize as many as possible of our nation's most promising future leaders to grow and strengthen the movement for educational equity and excellence." The organization aims to accomplish this by recruiting and selecting college graduates from top universities around the United States to serve as teachers. The selected members, known as "corps members," commit to teaching for at least two years in a public or public charter K–12 school in one of the 52 low-income communities that the organization serves.

Political Donations
$250
2011

The Republican National Committee (RNC) is a U.S. political committee that provides national leadership for the Republican Party of the United States. It is responsible for developing and promoting the Republican political platform, as well as coordinating fundraising and election strategy. It is also responsible for organizing and running the Republican National Convention. Similar committees exist in every U.S. state and most U.S. counties, although in some states party organization is structured by congressional district, allied campaign organizations being governed by a national committee. Reince Priebus is the current RNC Chairman.

$2,000
2010

Chairman at DiabetOmics, Inc.

$5,000
2009

Chairman at DiabetOmics, Inc.

Investments
Details Hidden

MediSpectra, Inc. develops and manufactures medical devices. The firm develops proprietary optical detection technology for enhanced accuracy and real time results in the detection of cancer & other human tissue abnormalities. Its technology is based on multimodal optical interrogation of tissues with light. The company was founded in 1995 and is headquartered in Lexington, MA.

Details Hidden

Senomyx, Inc. engages in the development and commercialization of flavor ingredients for the packaged food, beverage, and ingredient supply industries. It develops high intensity sweeteners, savory flavors, bitter taste blockers, and cooling agents. The company was founded by Paul A. Grayson, Lubert Stryer, Yon Chien Tsien, Denis Baylor, Harold McGee, and Charles Zuker on September 16, 1998 and is headquartered in San Diego, CA.

Details Hidden

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. Based on proprietary lipid conjugate technology, the company's two clinical stage compounds have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. CMX001 is a Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate. Its broad spectrum activity against double-stranded DNA (dsDNA) viruses without the myelotoxicity and nephrotoxicity of current agents has the potential to improve outcomes for immunosuppressed patients. Chimerix's second clinical-stage antiviral compound, CMX157 is a Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent tenofovir-diphosphate. It has the potential to directly address several limitations of current HIV and HBV therapies. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, influenza, malaria and other global public health needs.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Tim Wollaeger. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Tim Wollaeger's profile does not indicate a business or promotional relationship of any kind between RelSci and Tim Wollaeger.